Lexaria Bioscience Corp. (LEXX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 08-31. Amounts in USD.

Revenue Quarterly

0 70K 140K 210K Q4 '21: 31K Q1 '22: 13.9K Q2 '22: 30.6K Q3 '22: 99.7K Q4 '22: 111.2K Q1 '23: 97.7K Q2 '23: 20K Q3 '23: 77.7K Q4 '23: 30.7K Q1 '24: 151.3K Q2 '24: 145K Q3 '24: 84K Q4 '24: 84K Q1 '25: 183.9K Q2 '25: 174K Q3 '25: 174K Q4 '25: 174K Q1 '26: 0 Q2 '26: 20K Q3 '26: 0 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Gross Profit Quarterly

0 70K 140K 210K Q4 '21: 10.7K Q1 '22: 8.3K Q2 '22: 24.3K Q3 '22: 81.1K Q4 '22: 69.9K Q1 '23: 81.9K Q2 '23: 17.1K Q3 '23: 65K Q4 '23: 30.7K Q1 '24: 146.5K Q2 '24: 145K Q3 '24: 84K Q4 '24: 84K Q1 '25: 181.2K Q2 '25: 174K Q3 '25: 174K Q4 '25: 174K Q1 '26: 0 Q2 '26: 20K Q3 '26: 0 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q2 '18: -1.4M Q3 '21: -2.6M Q4 '21: -1.3M Q3 '22: -2.4M Q4 '22: -748.5K Q1 '23: -1.7M Q2 '23: -1.3M Q3 '23: -2.4M Q4 '23: -1.1M Q1 '24: -1.1M Q2 '24: -668K Q3 '24: -1.7M Q4 '24: -2.2M Q1 '25: -2.7M Q2 '25: -2.8M Q3 '25: -3.8M Q4 '25: -2.7M Q1 '26: -1.6M Q2 '26: -1.5M Q3 '26: -2M Q3 '21 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q4 '21: -1.2M Q1 '22: -2M Q2 '22: -1.4M Q3 '22: -2.4M Q4 '22: -1.5M Q1 '23: -1.8M Q2 '23: -1.3M Q3 '23: -2.4M Q4 '23: -1.2M Q1 '24: -1.2M Q2 '24: -649.5K Q3 '24: -1.8M Q4 '24: -2.2M Q1 '25: -2.7M Q2 '25: -2.7M Q3 '25: -3.8M Q4 '25: -2.7M Q1 '26: -1.6M Q2 '26: -1.4M Q3 '26: -2M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Cost of Revenue Quarterly

0 15K 30K 45K Q4 '21: 20.3K Q1 '22: 5.6K Q2 '22: 6.4K Q3 '22: 18.6K Q4 '22: 41.2K Q1 '23: 15.8K Q2 '23: 3K Q3 '23: 12.7K Q4 '23: 0 Q1 '24: 4.8K Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 2.7K Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '26: 0 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q4 '21: -1.1M Q1 '22: -1.2M Q2 '22: -1.3M Q3 '22: -1.3M Q4 '22: -1.2M Q1 '23: -1.2M Q2 '23: -1.2M Q3 '23: -1.8M Q4 '23: -1.6M Q1 '24: -1.2M Q2 '24: -619.6K Q3 '24: -1.3M Q4 '24: -1.9M Q1 '25: -2.7M Q2 '25: -1.5M Q3 '25: -3.6M Q4 '25: -2.6M Q1 '26: -984.1K Q2 '26: -2.2M Q3 '26: -1.6M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q1 '21: -809.5K Q1 '22: -1.2M Q2 '22: -1.3M Q3 '22: -1.3M Q4 '22: -1.2M Q1 '23: -1.3M Q2 '23: -1.2M Q3 '23: -1.8M Q4 '23: -1.6M Q1 '24: -1.2M Q2 '24: -619.6K Q3 '24: -1.3M Q4 '24: -1.9M Q1 '25: -2.8M Q2 '25: -1.5M Q3 '25: -3.6M Q4 '25: -2.6M Q1 '26: -984.1K Q2 '26: -2.2M Q3 '26: -1.6M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 9M 18M 27M Q4 '10: 12.7M Q2 '11: 13M Q3 '11: 13.1M Q4 '11: 14.3M Q2 '12: 16.4M Q3 '12: 16.4M Q4 '12: 16.4M Q1 '24: 9.1M Q2 '24: 10.8M Q3 '24: 13.9M Q1 '25: 16.7M Q2 '25: 17.5M Q3 '25: 18.3M Q1 '26: 21.4M Q2 '26: 24.4M Q3 '26: 24.8M Q2 '11 Q4 '11 Q3 '12 Q1 '24 Q3 '24 Q2 '25 Q1 '26 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q3 '19: -0.04 Q4 '19: -0.04 Q1 '20: -0.36 Q2 '20: -0.73 Q3 '20: -1.22 Q4 '20: -1.45 Q1 '21: -1.36 Q2 '21: -0.89 Q3 '21: -0.89 Q4 '21: -0.89 Q1 '22: -1.00 Q2 '22: -1.34 Q4 '24: -0.47 Q1 '25: -0.50 Q2 '25: -0.59 Q3 '25: -0.67 Q4 '25: -0.65 Q1 '26: -0.56 Q2 '26: -0.47 Q3 '26: -0.34 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.